| Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells M Strioga, S Viswanathan, A Darinskas, O Slaby, J Michalek Stem cells and development 21 (14), 2724-2752, 2012 | 978 | 2012 |
| Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature S Viswanathan, Y Shi, J Galipeau, M Krampera, K Leblanc, I Martin, ... Cytotherapy 21 (10), 1019-1024, 2019 | 588 | 2019 |
| International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials J Galipeau, M Krampera, J Barrett, F Dazzi, RJ Deans, J DeBruijn, ... Cytotherapy 18 (2), 151-159, 2016 | 492 | 2016 |
| Bone marrow mesenchymal stromal cell treatment in patients with osteoarthritis results in overall improvement in pain and symptoms and reduces synovial inflammation J Chahal, A Gómez-Aristizábal, K Shestopaloff, S Bhatt, A Chaboureau, ... Stem cells translational medicine 8 (8), 746-757, 2019 | 191 | 2019 |
| A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy BA Williams, AD Law, B Routy, V Gupta, XH Wang, A Chaboureau, ... Oncotarget 8 (51), 89256, 2017 | 142 | 2017 |
| TLR3 or TLR4 activation enhances mesenchymal stromal cell-mediated Treg induction via notch signaling I Rashedi, A Gómez-Aristizábal, XH Wang, S Viswanathan, A Keating Stem Cells 35 (1), 265-275, 2017 | 142 | 2017 |
| Mesenchymal stromal cell therapy: progress in manufacturing and assessments of potency KP Robb, JC Fitzgerald, F Barry, S Viswanathan Cytotherapy 21 (3), 289-306, 2019 | 137 | 2019 |
| Soliciting strategies for developing cell-based reference materials to advance mesenchymal stromal cell research and clinical translation S Viswanathan, A Keating, R Deans, P Hematti, D Prockop, DF Stroncek, ... Stem cells and development 23 (11), 1157-1167, 2014 | 136 | 2014 |
| Ligand/receptor signaling threshold (LIST) model accounts for gp130-mediated embryonic stem cell self-renewal responses to LIF and HIL-6 S Viswanathan, T Benatar, S Rose-John, DA Lauffenburger, PW Zandstra Stem Cells 20 (2), 119-138, 2002 | 126 | 2002 |
| Current concepts: the role of mesenchymal stem cells in the management of knee osteoarthritis JI Wolfstadt, BJ Cole, DJ Ogilvie-Harris, S Viswanathan, J Chahal Sports health 7 (1), 38-44, 2015 | 86 | 2015 |
| Towards predictive models of stem cell fate S Viswanathan, PW Zandstra Cytotechnology 41, 75-92, 2003 | 79 | 2003 |
| Synovial fluid monocyte/macrophage subsets and their correlation to patient-reported outcomes in osteoarthritic patients: a cohort study A Gómez-Aristizábal, R Gandhi, NN Mahomed, KW Marshall, ... Arthritis Research & Therapy 21, 1-10, 2019 | 77 | 2019 |
| Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model BE Swift, BA Williams, Y Kosaka, XH Wang, JA Medin, S Viswanathan, ... Haematologica 97 (7), 1020, 2012 | 74 | 2012 |
| Supplementation‐dependent differences in the rates of embryonic stem cell self‐renewal, differentiation, and apoptosis S Viswanathan, T Benatar, M Mileikovsky, DA Lauffenburger, A Nagy, ... Biotechnology and bioengineering 84 (5), 505-517, 2003 | 65 | 2003 |
| 19F-perfluorocarbon-labeled human peripheral blood mononuclear cells can be detected in vivo using clinical MRI parameters in a therapeutic cell setting C Fink, JM Gaudet, MS Fox, S Bhatt, S Viswanathan, M Smith, J Chin, ... Scientific reports 8 (1), 590, 2018 | 64 | 2018 |
| Bringing regenerative medicines to the clinic: the future for regulation and reimbursement T Bubela, C McCabe, P Archibald, H Atkins, SE Bradshaw, P Kefalas, ... Regenerative medicine 10 (7), 897-911, 2015 | 56 | 2015 |
| Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predisposition J Galipeau, M Krampera, K Leblanc, JA Nolta, DG Phinney, Y Shi, K Tarte, ... Cytotherapy 23 (5), 368-372, 2021 | 54 | 2021 |
| Cell-based therapies for coronavirus disease 2019: proper clinical investigations are essential M Khoury, PRM Rocco, DG Phinney, M Krampera, I Martin, ... Cytotherapy 22 (11), 602-605, 2020 | 43 | 2020 |
| A systematic study of the effect of different molecular weights of hyaluronic acid on mesenchymal stromal cell-mediated immunomodulation A Gómez-Aristizábal, KP Kim, S Viswanathan PLoS One 11 (1), e0147868, 2016 | 41 | 2016 |
| Recent progress on developing exogenous monocyte/macrophage-based therapies for inflammatory and degenerative diseases MWY Chan, S Viswanathan Cytotherapy 21 (4), 393-415, 2019 | 35 | 2019 |
